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Abstract
Capric acid is a second medium-chain fatty acid, and recent studies have shown that fatty acids are associated with bone
density and reduce bone turnover. In this study, we investigated the effects of capric acid on lipopolysaccharide (LPS)-
induced osteoclastogenesis in RAW264.7 cells. After treatment with capric acid (1 mM), the number of tartrate resistant acid
phosphatase (TRAP)-positive cells decreased significantly. Capric acid reduced LPS-induced TRAP expression, an osteoclast
differentiation marker, without inhibiting cell viability. LPS strongly upregulated inducible nitric oxide synthase (iNOS)
mRNA levels and nitric oxide (NO) production, whereas capric acid inhibited them. Furthermore, capric acid also inhibited
monocyte chemoattractant protein-1 (MCP-1) mRNA expression. Subsequently, we investigated various intracellular
signaling proteins, including nuclear factor-kB (NF-kB), c-Jun-N-terminal kinase (JNK), extracellular signal regulated kinase 1/
2 (ERK1/2), and signal transducer and activator of transcription 1 (STAT1) and STAT3 associated with osteoclastogenesis.
Capric acid had no effects on LPS-induced activation of the NF-kB, JNK, ERK1/2, and STAT1 pathways. However, capric acid
inhibited LPS-induced phosphorylation of Ser
727 in STAT3. Additionally, stattic (a STAT3 inhibitor) inhibited LPS-induced
iNOS and MCP-1 gene expression. In conclusion, we demonstrated that capric acid inhibited LPS-induced osteoclastogen-
esis by suppressing NO production via the STAT3 pathway. These results suggest that capric acid has important therapeutic
implications for treating bone diseases associated with excessive osteoclastogenesis.
Citation: Park E-J, Kim SA, Choi Y-M, Kwon H-K, Shim W, et al. (2011) Capric Acid Inhibits NO Production and STAT3 Activation during LPS-Induced
Osteoclastogenesis. PLoS ONE 6(11): e27739. doi:10.1371/journal.pone.0027739
Editor: Jeong-Sun Seo, Seoul National University College of Medicine, Korea
Received May 15, 2011; Accepted October 24, 2011; Published November 16, 2011
Copyright:  2011 Park et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Basic Science Research Program through the NRF of Korea funded by the MEST (2010-0015356). This work was also
partly supported by a grant from the Korea Food & Drug Administration (10182KFDA992-2302) and the Priority Research Centers Program (NRF 2010-0028294).
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: sangdunchoi@ajou.ac.kr
. These authors contributed equally to this work.
Introduction
Osteoclasts are mainly derived from bone marrow hematopoi-
etic monocyte/macrophage lineages. Osteoclasts are formed
through multiple steps, including cell-to-cell contact, fusion, and
differentiation [1]. Osteoclasts are characterized by high expres-
sion of tartrate resistant acid phosphatase (TRAP), which can be
used as a cytochemical marker for osteoclasts and their precursors.
Increased osteoclast activity leads to bone loss and eventually to
bone diseases such as induced rheumatoid arthritis and osteopo-
rosis [2,3,4,5,6]. Therefore, regulation of osteoclastogenesis plays a
key role in bone homeostasis.
Cell fusion plays a critical role controlling osteoclastogenesis.
Nitric oxide (NO) and monocyte chemoattractant protein-1
(MCP-1) enhance osteoclastogenesis by mediating cell fusion.
NO also increases osteoclast formation by increasing actin
remodeling in mononuclear pre-osteoclasts, thereby mediating
fusion and formation of multinucleated osteoclasts [7]. NO is a
short-lived free radical involved in the regulation of many
physiological processes such as vascular relaxation, neurotrans-
mission, platelet aggregation, and the immune response [8,9].
Furthermore, it is generated from oxygen and L-arginine by nitric
oxide synthase (NOS). Three isoforms of NOS have been
identified: a neuronal form (nNOS or NOS1), an endothelial
form (eNOS or NOS3), and an inducible form (iNOS or NOS2).
Among these three NOS, iNOS is expressed in response to various
inflammatory stimuli and results in the production of a large
amount of NO by macrophages during inflammation [10,11].
Receptor activator of nuclear factor-kB ligand (RANKL) and
macrophage colony-stimulating factor are both considered neces-
sary and sufficient for osteoclast formation [1]. Recent studies have
reported that lipopolysaccharide (LPS) induces osteoclast differ-
entiation and increases bone loss [12].
LPS, a bacteria-derived cell wall product, has long been
recognized as a key factor in the development of bone loss [13].
LPS plays an important role in bone resorption, which involves
recruitment of inflammatory cells, synthesis of cytokines [such as
interleukin-6 (IL-6), and tumor necrosis factor-a (TNF-a)], and
activation of osteoclast formation and differentiation [12]. LPS
induces the production of pro-inflammatory mediator by osteo-
clasts via the nuclear factor-kB (NF-kB) pathway and the three
major mitogen-activated protein kinases (MAPKs), extracellular
signal regulated kinase 1/2 (ERK1/2), c-Jun-N-terminal kinase
(JNK), and p38 [14,15,16].
Another important transcription factor involved in inflamma-
tory cytokine induction is signal transducer and activator of
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regulation of genes involved in the acute phase of the
inflammatory response, cell growth, and cell differentiation [17].
The ability of STAT family proteins to homo or heterodimerize
alters gene transcription based upon their binding to specific
response elements in the promoters of target genes [18,19,20]. In
previous studies, it was shown that the promoter region of the
iNOS gene in murine macrophage contains a STAT-binding
gamma-activated site (GAS) [21]. STAT3 is involved in LPS-
induced expression of iNOS and is partly dependent on Ser
727
phosphorylation, which is also necessary for nuclear translocation
and DNA binding [22]. Activated STAT3 also participates in the
regulation of cell growth, differentiation, and survival and is
essential for gp130-mediated osteoclast formation [23]. Another
STAT3 target gene, MCP-1/chemokine (C–C motif) ligand 2
(Ccl2), is a chemokine belonging to the CC chemokine family that
plays a critical role in the recruitment and activation of leukocytes
during acute inflammation [24]. MCP-1 plays a critical role in the
pathogenesis of arteriosclerosis and other vascular diseases by
recruiting monocytes into the arterial wall [25]. Furthermore,
MCP-1 has been implicated in cell–cell fusion of osteoclasts [26].
Capric acid, a medium chain fatty acid, is an important
ingredient of coconut oil and enhances the immune system by
acting as a reinforcing agent. Recently, there has been increasing
evidence that deficiency of certain fatty acids may contribute to
bone loss [27]. Several milk fractions and fatty acids also inhibit
osteoclastogenesis in bone marrow cultures and RAW264.7 cells
[28]. Fatty acids, which are merely carboxylic acids with long
hydrocarbon chains, are an important source of fuel for many
tissues such as heart and skeletal muscles. Based on several studies,
we have extended this approach to assess the effects of capric acid
in osteoclastogenesis.
In this study, we investigated the effect of capric acid on LPS-
induced osteoclast differentiation in RAW264.7 cells. To under-
stand the mechanism of capric acid, we analyzed the signal
transduction pathways of NF-kB, JNK, ERK1/2, and STAT.
Results
Effects of capric acid on LPS-induced RAW264.7 cells
Previous studies have demonstrated that LPS induces osteoclast
formation in RAW264.7 cells [12,14,29]. In our work, we have
also used RAW264.7 cells, which can differentiate into osteoclast-
like cells in the presence of LPS. To measure LPS-induced
morphological changes in response to capric acid, we treated
RAW264.7 cells with various concentrations of capric acid (0.1,
0.25, and 1 mM). As shown in Fig. 1, the control group and capric
acid-treated groups (0.1, 0.25, and 1 mM) did not show any
morphological changes, whereas the LPS-treated (1 mg /ml) group
showed morphological changes. Furthermore, capric acid at 0.1,
0.25, and 1 mM induced cell proliferation by 104.963.6,
112.461.3, and 122.469.5% of the control (100%), respectively,
and reduced the LPS-induced cytotoxic effect by 91.967.7,
98.664.3, and 113.167.5% of the control (100%) when compared
to LPS only (89.068.5%), respectively (Fig. 2).
Capric acid inhibits TRAP-positive multinucleated cell
formation
LPS causes the formation of TRAP-positive multinucleated
giant RAW264.7 cells [12]. Therefore, we examined the effects of
capric acid on osteoclast differentiation in LPS-induced
RAW264.7 cells using TRAP staining, a marker of osteoclasts.
We confirmed LPS-induced osteoclast formation in RAW264.7
cells over 1–3 days (Fig. 3). Multinucleated cell formation was
observed during the first 2 days after LPS stimulation, although
there was still a small number of TRAP-positive mononuclear
cells. Our results show that TRAP-positive cells were decreased
significantly by capric acid (1 mM) (Fig. 3A). Moreover, LPS-
stimulated TRAP mRNA (an osteoclast-specific gene) expression
was also inhibited by capric acid (Fig. 3C).
Capric acid inhibits LPS-induced NO production in
RAW264.7 cells
NO is generated by iNOS and affects osteoclast formation and
function. NO enhances osteoclastogenesis by mediating cell fusion
[7]. To examine the effects of capric acid on LPS-induced NO
production, we treated RAW264.7 cells with capric acid for 12,
18, and 24 hr. The results showed that capric acid significantly
inhibited LPS-induced NO production at all tested time points
(Fig. 4). Hence, our results indicate that capric acid suppressed
LPS-induced osteoclast formation by inhibiting NO production.
Capric acid inhibits LPS-induced iNOS and MCP-1 gene
upregulation in RAW264.7 cells
Because MCP-1 is reportedly involved in osteoclast cell-cell
fusion and differentiation, we next examined the effects of capric
acid on LPS-induced expression of iNOS and MCP-1 by RT-PCR
[30]. Treatment with LPS alone markedly increased iNOS and
MCP-1 gene expression, whereas treatment with capric acid
significantly inhibited iNOS and MCP-1 expression (Fig. 5). iNOS
and cylcooxygenase-2 (COX-2) protein expression increased
following LPS treatment but decreased following capric acid
treatment (Fig. 5D).
Capric acid inhibits LPS-induced phosphorylation of
Ser
727 STAT3 in RAW264.7 cells
Previous studies have shown that osteoclastogenesis is promoted
by activating various intracellular signaling pathways, including
MAPKs, such as JNK, ERK, and P38 and transcription factors,
such as NF-kB, NFATc1, and STAT [31,32]. To clarify the
molecular mechanism of capric acid during LPS-stimulated
osteoclast formation, we measured transcription factor expression
and phosphorylation of various signaling molecules by Western
blot analysis. We treated cells with LPS for 0, 5, 15, 30, 60, and
120 min in the absence or presence of capric acid, after which
activation of ERK1/2, JNK, NF-kB, STAT1, and STAT3 was
determined. Capric acid had no effect on LPS-stimulated
activation of NF-kB, JNK, or ERK1/2 or expression of TNF-a,
IL-1b, or IL-6 (Fig. 6A and C). As shown in Fig. 6B, LPS-induced
phosphorylation of STAT3 Ser
727 was inhibited by capric acid.
How capric acid inhibits LPS-induced STAT3 phosphorylation
still remains to be determined. Additionally, we used stattic, an
inhibitor of STAT3, to determine whether or not LPS-induced
expression of iNOS and MCP-1 is regulated through STAT3
activation. The results showed that LPS-induced iNOS and MCP-
1 gene expression was inhibited by stattic. Additionally, COX-2
and iNOS gene expression decreased when treated with STAT3
siRNA (Fig. 6D). These results suggest that capric acid suppressed
LPS-stimulated osteoclast formation via the STAT3 pathway in
RAW264.7 cells.
Discussion
We demonstrated that capric acid inhibits LPS-induced
osteoclastogenesis in RAW264.7 cells. One of the key factors in
osteoclastogenesis, which is induced by osteoblasts, is activation of
the RANKL receptor [33,34]. Bone mass is controlled by the
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PLoS ONE | www.plosone.org 2 November 2011 | Volume 6 | Issue 11 | e27739balance between the activities of osteoblasts and osteoclasts.
Osteoclasts are multinuclear cells formed by cell fusion and are
characterized by high TRAP expression. Recently, it was reported
that LPS-induced osteoclast formation does not require RANKL
and M-CSF [12]. Moreover, Hotokezaka et al. showed that
RANKL-independent cell fusion of osteoclast-like cells can be
induced by TNF-a, LPS, and peptidoglycans [14]. RAW264.7
cells act as osteoclast progenitors and differentiate into osteoclasts
in response to LPS. In this study, we determined the effects of
capric acid on LPS-induced osteoclast formation in RAW264.7
cells using the TRAP staining method. TRAP staining is used to
stain TRAP in osteoclasts. Alkaline phosphatase and TRAP are
used as markers for osteoblasts and osteoclasts, respectively.
According to our results, LPS increased the formation of TRAP-
positive multinucleated cells and TRAP gene expression, as shown
by TRAP staining and RT-PCR. However, these events were
inhibited by capric acid (Fig. 2). Therefore, we concluded
that capric acid inhibits LPS-induced TRAP-positive osteoclast
formation.
NO, an important multifunctional signaling molecule in bone, is
produced by various cells at basal or stimulated levels. NO
regulates bone formation, resorption, remodeling, mechanotrans-
duction, and repair under physiological or pathophysiological
conditions. NO produced endogenously or supplied by NO donors
exerts potent biphasic actions that profoundly affect the recruit-
ment, proliferation, differentiation, activity, and/or survival of
osteoclasts and osteoblasts, their precursors, and other cells within
the bone [35,36,37]. Low levels of NO may support osteoblast
bone formation and osteoclast-mediated bone remodeling (both
basal and cytokine-induced) [38,39], whereas high NO levels and
NO-generating compounds inhibit osteoclast formation and bone
resorption and prevent bone loss during severe inflammation or in
estrogen-deficient animals [40,41,42]. Here, we report that capric
acid inhibited NO production and iNOS mRNA expression
(Figs. 3 and 4). Therefore, our results showed that LPS-induced
NO production is inhibited by capric acid, whereas NO may act as
a mediator of osteoclast formation.
Next, we considered which signaling molecules affect LPS-
induced NO production and iNOS expression. There are a large
number of binding sites for transcription factors in the iNOS
region, including NF-kB, AP1, STATs, and CCAAT/enhancer-
binding protein (C/EBP), based on cell type and stimulus [43].
Among the transcription regulators in the promoter regions of
iNOS, NF-kB seems to be essential for LPS-induced inflammatory
cytokine production [44]. An abundant amount of pro-inflamma-
tory cytokines at sites of inflammation promotes osteoclast
differentiation and activation. However, our results showed no
effect of capric acid on the NF-kB pathway, consistent with the
Figure 1. Morphological alteration of RAW264.7 cells treated with lipopolysaccharide (LPS) and capric acid. RAW264.7 cells were
treated with 1 mg/ml of LPS with or without capric acid (0.1, 0.25, and 1 mM) for 24 hr.
doi:10.1371/journal.pone.0027739.g001
Figure 2. Cell viability of RAW264.7 cells treated with
lipopolysaccharide (LPS) and capric acid. RAW264.7 cells were
treated with or without 1 mg/ml of LPS and with capric acid (0.1, 0.25,
and 1 mM) for 24 hr.
doi:10.1371/journal.pone.0027739.g002
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absence or presence of capric acid for 1–3 days, and then cells were fixed and stained for tartrate resistant acid phosphatase (TRAP), respectively. (A)
Multinucleated cells were observed on day 2. (a) control, (b) capric acid, (c) LPS only, (d) LPS + capric acid, (B) TRAP-positive cells were counted as
osteoclasts on day 2. (C) RAW264.7 cells were cultured with LPS in the absence or presence of capric acid for 24 hr. Total RNA was isolated using Trizol
reagent, and mRNA levels were determined by RT-PCR using primers for TRAP and GAPDH. Values are expressed as the mean 6 SEM from triplicate
cultures. *p,0.05: significantly different from the LPS-treated value.
doi:10.1371/journal.pone.0027739.g003
Figure 4. Effects of capric acid on lipopolysaccharide (LPS)-induced nitric oxide (NO) production. RAW264.7 cells were incubated with
1 mg/ml of LPS in the absence or presence of 1 mM capric acid for 12, 18, and 24 hr. The media was harvested 24 hr later and assayed for NO. Data
represent the mean 6 SEM for three independent experiments. *p,0.05: significantly different from the LPS-treated value.
doi:10.1371/journal.pone.0027739.g004
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of the pro-inflammatory cytokines IL-1b, TNF-a, or IL-6 (Fig. 5B
and C).
STAT is another key signaling molecule involved in the
cytokine-induced inflammatory response [45]. Among the STAT
family, STAT3 is an important transcription factor for regulating
iNOS gene expression, and STAT3 DNA binding is affected by
phosphorylation of Ser 727 or/and Tyr 705 [46]. Previous studies
have shown that a STAT-binding GAS (interferon-gamma
activated sequence) is necessary for iNOS expression in LPS-
induced RAW264.7 cells [47]. Furthermore, STAT3 mutant mice
exhibit decreased bone density, bone volume, and an increased
number of TRAP-positive osteoclasts [48]. These results suggest
that STAT3 plays a negative role in the regulation of
osteclastogenesis. Our present study found that treatment with
LPS alone markedly increased STAT3 phosphorylation at Ser
727, whereas phosphorylation was decreased strongly by capric
acid (Fig. 5B). As shown in Fig. 4, capric acid inhibited iNOS and
MCP-1 gene expression (STAT3 target genes). Additionally, LPS-
induced iNOS and MCP-1 mRNA expression was inhibited by the
STAT3 inhibitor stattic (Fig. 5D). Based on these findings, we
concluded that capric acid exerts a potent inhibitory effect by
inhibiting iNOS expression and by activating STAT3 (Ser 727) in
LPS-treated RAW264.7 cells.
In conclusion, we demonstrated the inhibitory effects of capric
acid on LPS-induced osteoclastogenesis by targeting NO produc-
tion via the STAT3 pathway. Fatty acids are important
components of a normal diet, and the manipulation of dietary
fatty acid composition may influence bone resorption, bone
formation, and bone mass. Further elucidation of the mechanism
of capric acid regulation should contribute to the discovery of
novel therapeutic approaches for treating various types of
inflammatory bone destruction.
Materials and Methods
Cell culture
RAW264.7, a mouse macrophage cell line, was obtained from
the ATCC (Rockville, MD, USA). Cells were cultured in 10 mm
plates and maintained in high glucose Dulbecco’s Modified Eagle
Medium (DMEM) supplemented with 2 mM glutamine, antibiot-
ics (1% penicillin/streptomycin), and 10% heat-inactivated fetal
bovine serum (FBS) in a 37uC humidified incubator containing 5%
CO2.
Figure 5. Capric acid suppresses lipopolysaccharide (LPS)-induced expression of inducible nitric oxide synthase (iNOS) and
monocyte chemoattractant protein-1 (MCP-1) in RAW264.7 cells. (A) RAW264.7 cells were cultured with 1 mg/ml of LPS in the absence or
presence of 1 mM capric acid for 24 hr. Total RNA was isolated using Trizol reagent, and mRNA levels were determined by RT-PCR using specific
primers to iNOS, MCP-1, and GAPDH. (B, C) GAPDH gene expression levels are relative values, which were normalized. (D) RAW264.7 cells were
cultured with 1 mg/ml of LPS in the absence or presence of 1 mM capric acid for 24 hr. Changes in protein expression following treatment with capric
acid were measured using specific antibodies against iNOS, cyclooxygenase-2 (COX-2), and b-actin.
doi:10.1371/journal.pone.0027739.g005
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LPS, capric acid, L-NMMA, and a TRAP kit were purchased
from Sigma-Aldrich (St. Louis, MO, USA). Antibodies specific to
p-JNK, JNK, p-ERK, and ERK along with horseradish
peroxidase (HRP)-conjugated rabbit and mouse IgG antibodies
were purchased from Cell Signaling Technology (Danvers, MA,
USA). Antibodies to IkB-a were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). An NO detection kit was
purchased from iNtRON Biotech (Seoul, Korea). An RNeasy mini
kit was purchased from Qiagen Inc. (Valencia, CA, USA).
TRAP staining
RAW264.7 cells were plated at a density of 5610
5 cells/well in
24-well plates for 12 hr and then treated with the indicated
compounds for an additional 24, 48, and 72 hr. The supernatant
was removed, and the cells were washed twice with PBS. Fixation
solution was added to the cells and then removed with PBS. TRAP
staining solution (50 mM acetate buffer, 30 mM sodium tartrate,
0.1 mg/ml of Naphtol AS-MX phosphate, 0.1% w/v Triton X-
100, and 0.3 mg/ml of Fast Red Violet LB stain) was added to the
cells for 1 hr. The solution was then removed, and the cells were
washed twice with PBS. Cell morphology was detected by
microscopic observation.
3-[4,5-dimetylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide (MTT) assay
Cell viability was determined using a colorimetric 3-[4,5-
dimetylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) as-
say. RAW264.7 cells (5610
4 cells/well) were cultured in 96-well
plates for 24, 48, and 72 hr after LPS treatment with or without
capric acid. MTT solution (20 ml; 5 mg/ml) was added, and the
cells were incubated at 37uC for an additional 4 hr. After washing
out the supernatant, the insoluble formazan product was dissolved
in DMSO. Then, the optical density of the 96-well culture plates
was measured using an ELISA reader at 570 nm. The optical
density of formazan formed in the untreated control cells was
considered 100% viability.
NO analysis
RAW264.7 cells were plated at a density of 5610
4 cells/well in
96-well plates for 12 hr and then treated with the indicated
compounds for an additional 12, 18, and 24 hr. The supernatant
from the cultured cells was centrifuged to remove cell debris and
transferred to 96-well plates. The supernatant was then reacted
using a nitric oxide detection kit (iNtRON Biotech). Values were
calculated by measuring the absorbance at 540 nm using a plate
reader.
RT-PCR
RAW264.7 cells were treated with each of the compounds
(1 mg/ml LPS and 1 mM capric acid) for 24, 48, and 72 hr,
followed by washing with PBS. Total RNA was isolated with an
RNeasy Mini kit (Qiagen), and the total RNA concentration was
detected using a spectrophotometer. Total RNA (1 mg) was
converted to cDNA with cDNA Synthesis Master Mix (GenDE-
POT; Barker, TX, USA). PCR was performed using Maxim PCR
Premix (iNtRON Biotech). The PCR primers were as follows:
TRAP- F; 59-TCC CCT GGT ATG TGC TGG-39 and R; 59-
GCA TTT TGG GCT GCT GA-39, iNOS- F; 59-GCA GAA
TGT GAC CAT CAT GG-39 and R; 59-ACA ACC TTG GTG
TTG AAG GC-39, MCP-1- F; 59-GAA GGA ATG GGT CCA
GAC AT-39 and R; 59-ACG GGT CAA CTT CAC ATT CA-39,
Figure 6. Effects of capric acid in RAW264.7 cells. (A, B) RAW264.7 cells were cultured with lipopolysaccharide (LPS) in the absence or presence
of capric acid for 5, 15, 30, 60, and 120 min. The amounts of IkB-a, p-JNK, p-ERK1/2, p-STAT1, and p-STAT3 were determined by Western blot analysis.
b-actin was used as an internal control. (C) RAW264.7 cells were cultured with 1 mg/ml of LPS in the absence or presence of stattic for 24 hr. Total RNA
was isolated using Trizol reagent, and mRNA levels were determined by RT-PCR using primers specific to inducible nitric oxide synthase (iNOS),
monocyte chemoattractant protein-1 (MCP-1), and GAPDH. All analyses were representative of at least three independent experiments. (D) Effects of
capric acid or siRNAs of STAT3. STAT3 siRNA sequence #1: sense, 59-GAA CAA CAU GUC AUU UGC UUU-39, antisense, 59-AGC AAA UGA CAU GUU
GUU CUU-39; STAT3 siRNA sequence #2: sense, 59-UCA UCA UGG GCU AUA AGA UUU-39, antisense, 59-AUC UUA UAG CCC AUG AUG AUU-39.
doi:10.1371/journal.pone.0027739.g006
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59-ATG CTC CTG CTT GAG TAT GT-39, STAT3- F; 59-AGA
ACC TCC AGG ACG ACT TTG-39 and R; 59-TCA CAA TGC
TTC TCC GCA TCT-39, GAPDH-F; 59-CAT GAC CAC AGT
CCA TGC CAT CAC T-39 and R; 59-TGA GGT CCA CCA
CCC TGT TGC TGT A-39, The amplification sequence protocol
was conducted at 95uC for 30 s, 58uC for 30 s, and 72u for 45 s for
each cycle. PCR products were separated by electrophoresis on
1% agarose gels and visualized with ethidium bromide staining.
Western blot analysis
RAW264.7 cells were lysed in protein extraction solution
(iNtRON Biotech). The lysate was centrifuged at 13,000 rpm for
20 min at 4uC to remove cellular debris. Protein concentrations of
the extracts were determined by the Bradford assay (Bio-Rad
Laboratories; Hercules, CA, USA). Equal amounts of protein were
separated by SDS polyacrylamide gel electrophoresis, transferred
to a nitrocellulose membrane, and blocked with 5% skim milk in
TBST for 1 hr. The membranes were then incubated with various
primary antibodies, which were diluted with TBST at 4uC with
gentle shaking overnight. After washing, the membrane was
incubated with HRP-goat anti-mouse IgG (H + L) conjugate
antibody (Zymed Laboratories; San Francisco, CA, USA) diluted
in TBST (1:2,000) for 1 hr. After washing several times with
TBST, the blots were visualized with enhanced chemilumines-
cence reagents (Amersham Biosciences; Chalfont, Buckingham-
shire, UK).
siRNA transfection
siRNAs targeting STAT3 mRNA were designed and purchased
from Genolution Pharmaceuticals (Seoul, Korea). The TransIT-
TKOH reagent from Mirus Bio (Madison, WI, USA) was used for
siRNA delivery. RAW264.7 cells were seeded at 3610
5 cells/well
in 6-well plates containing 2.5 ml DMEM and 10% FBS for 12 hr.
DMEM (250 ml) containing 10 nM of siRNA and 7.5 mlo f
TransIT-TKOH reagent were incubated at room temperature for
30 min and added to each well. After a transfection with STAT3
siRNA for 24 hr, the medium was replaced with normal medium
and used for the next experiments.
Statistical analysis
Statistical analyses were performed using SPSS (Statistical
Package for the Social Sciences) ver. 12.0 software (SPSS, Inc.,
Chicago, IL, USA). Each datum represents the mean 6 SEM for
different experiments under the same conditions. Statistical
significance was compared between each treated group and the
control using the independent t- test. P values ,0.05 were
considered statistically significant.
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